Published in Blood Cancer J on March 01, 2013
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol (2013) 1.03
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One (2013) 0.93
Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res (2015) 0.80
Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation. Adv Virol (2015) 0.79
The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget (2014) 0.79
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS (2016) 0.75
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica (2015) 0.75
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol (2015) 0.75
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. Oncol Lett (2016) 0.75
HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress. PLoS One (2015) 0.75
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. Onco Targets Ther (2017) 0.75
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Plasma cell differentiation requires the transcription factor XBP-1. Nature (2001) 9.72
Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol (2008) 4.10
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct (1998) 3.48
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
A proteolytic system that compensates for loss of proteasome function. Nature (1998) 1.76
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther (2008) 1.65
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med (2002) 1.59
The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS (1999) 1.52
Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol (2009) 1.49
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol (2012) 1.46
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia (2009) 1.40
The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 1.40
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget (2010) 1.40
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica (2011) 1.31
Antitumour effects of antiretroviral therapy. Nat Rev Cancer (2004) 1.20
Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS (2002) 1.14
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol (2011) 1.14
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia (2006) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS (2008) 1.12
HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther (2004) 1.11
Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res (2002) 1.08
How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem (1999) 1.07
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther (2008) 1.01
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis (2012) 1.00
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood (2005) 0.99
Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res (2011) 0.99
An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer (2009) 0.93
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica (2012) 0.88
Activity and subcellular distribution of cathepsins in primary human monocytes. J Leukoc Biol (2003) 0.86
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. AIDS (2003) 0.86
Nelfinavir mesylate. Expert Opin Pharmacother (2000) 0.82
Signaling pathways in adenoid cystic cancers: implications for treatment. Cancer Biol Ther (2009) 0.81
Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res (2006) 0.81
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Antibiotic resistance of faecal Escherichia coli in poultry, poultry farmers and poultry slaughterers. J Antimicrob Chemother (2001) 2.76
Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res (2011) 2.06
Action of polymyxin B on bacterial membranes. 1. Binding to the O-antigenic lipopolysaccharide of Salmonella typhimurium. Z Naturforsch C (1974) 2.06
A mutation in a rous sarcoma virus gene that controls adenosine 3',5'-monophosphate levels and transformation. J Biol Chem (1972) 1.56
Enterococci with glycopeptide resistance in turkeys, turkey farmers, turkey slaughterers, and (sub)urban residents in the south of The Netherlands: evidence for transmission of vancomycin resistance from animals to humans? Antimicrob Agents Chemother (1999) 1.56
Proteases involved in MHC class II antigen presentation. Immunol Rev (1999) 1.54
Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countries. J Antimicrob Chemother (2004) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Action of polymyxin B on bacterial membranes. Binding capacities for polymyxin B of inner and outer membranes isolated from Salmonella typhimurium G30. Arch Microbiol (1976) 1.52
The effectiveness of sealants in managing caries lesions. J Dent Res (2008) 1.52
Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med (2000) 1.49
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia (2009) 1.40
Degradation of urea herbicides by cell-free extracts of Bacillus sphaericus. Appl Microbiol (1970) 1.34
Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. Immunity (2001) 1.29
The population structure of Staphylococcus aureus among general practice patients from The Netherlands. Clin Microbiol Infect (2009) 1.24
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia (2006) 1.13
Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol (2001) 1.07
Poly(ADP-ribose)glycohydrolase is an upstream regulator of Ca2+ fluxes in oxidative cell death. Cell Mol Life Sci (2010) 1.07
Purification and some properties of a hitherto-unknown enzyme reducing the carbon-carbon double bond of alpha, beta-unsaturated carboxylate anions. Eur J Biochem (1979) 1.01
The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J (2001) 1.00
Quantitative correlation of uptake with antibiotic activity of polymyxin B in Salmonella typhimurium. FEBS Lett (1971) 0.98
Action of polymyxin B on bacterial membranes: phosphatidylglycerol- and cardiolipin-induced susceptibility to polymyxin B in Acholeplasma laidlawii B. Antimicrob Agents Chemother (1976) 0.95
Chromatin structure and cellular radiosensitivity: a comparison of two human tumour cell lines. Int J Radiat Biol (1996) 0.92
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol (2008) 0.92
Stimulation of human peripheral blood mononuclear cells by zinc and related cations. Cytokine (1996) 0.89
Prostate cancer: are new prognostic markers on the horizon? Prostate Cancer Prostatic Dis (2000) 0.89
Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg (1990) 0.87
DNA damage induction and tumour cell radiosensitivity: PFGE and halo measurements. Int J Radiat Biol (1998) 0.86
Cellular and humoral parameters for vascular damage in blood during cytomegalovirus infections. Transplant Proc (2001) 0.86
Evidence-based dentistry and the dental research community. J Dent Res (1999) 0.85
How dentists see themselves, their profession, the public. J Am Dent Assoc (1992) 0.85
Influence of cefazolin prophylaxis and hospitalization on the prevalence of antibiotic-resistant bacteria in the faecal flora. J Antimicrob Chemother (2002) 0.84
LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler Thromb Vasc Biol (1996) 0.82
[Effect of polymyxin B on membranes and membrane components of Salmonella typhimurium]. Zentralbl Bakteriol Orig A (1974) 0.82
On a hitherto unknown fermentation path of several amino acids by proteolytic clostridia. FEBS Lett (1982) 0.82
Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. EMBO J (2000) 0.81
Immunogenicity and safety of a liquid combination of DTP-PRP-T [corrected] vs lyophilized PRP-T reconstituted with DTP. Vaccine (1997) 0.81
Intravenous or oral adjuvant CMF for node-positive breast cancer. Aust N Z J Surg (1992) 0.81
Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. J Pept Sci (2005) 0.81
Utilization of (E)-2-butenoate (crotonate) by Clostridium kluyveri and some other Clostridium species. Arch Microbiol (1980) 0.80
Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol (1999) 0.80
The activities of hydrogenase and enoate reductase in two Clostridium species, their interrelationship and dependence on growth conditions. Arch Microbiol (1980) 0.79
Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis (1991) 0.79
[Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis]. Fortschr Neurol Psychiatr (2011) 0.79
Concentrations of nonesterified fatty acids and glucose in blood of periparturient dairy cows are indicative of pregnancy success at first insemination. J Dairy Sci (2012) 0.78
Chiral products from non-pyridine nucleotide-dependent reductases and methods for NAD(P)H regeneration. Ciba Found Symp (1985) 0.78
Incorporation of labeled precursors into the RNA and proteins of lactic dehydrogenase virus. J Virol (1973) 0.78
Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection. J Infect Dis (2000) 0.77
Risks of the "big three": what dentists and patients believe about dental amalgam, fluoride and HIV. J Am Dent Assoc (1992) 0.77
Mitochondria catalyze the reduction of NAD by reduced methylviologen. FEBS Lett (1987) 0.76
Molecular typing of methicillin-susceptible Staphylococcus aureus isolates collected in the Yogyakarta area in Indonesia, 2006. Clin Microbiol Infect (2010) 0.76
Wish for privacy for young and old. J Gerontol (1970) 0.76
Cardiac response to exercise in normal-weight and obese, Hispanic men and women: implications for exercise prescription. Acta Physiol (Oxf) (2011) 0.76
A flawed report on fractures? J Am Dent Assoc (2001) 0.75
Locally advanced breast cancer current status and future directions. Int J Radiat Oncol Biol Phys (1989) 0.75
Assessment of the medial collateral ligament as an intra-operative anatomical landmark for tibial plateau levelling osteotomy. Vet Comp Orthop Traumatol (2014) 0.75
Stereospecific reductions of 2-en-1-ols catalyzed by Clostridium kluyveri. Hoppe Seylers Z Physiol Chem (1981) 0.75
[Extramedullary myeloma manifestations: imaging findings]. Rofo (2006) 0.75
[Induced fibrogenesis and intraosseous implants]. Dent Cadmos (1965) 0.75
[Relationship between the binding and effect of 14 C-polymyxin B on Salmonella typhimurium (brief report)]. Zentralbl Bakteriol Orig A (1972) 0.75
Flasking technique for large facial prostheses. J Prosthet Dent (1979) 0.75
[Chronic periodontosis]. Cah Odontostomatol Touraine (1969) 0.75
[Functional variations in the arteriovenous glomi of the periodontium]. Actual Odontostomatol (Paris) (1970) 0.75
Task force on innovation in dental hygiene curricula. J Dent Educ (1989) 0.75
[General considerations on periodontosis]. Cah Odontostomatol Touraine (1969) 0.75
Health services research in dental public health. J Public Health Dent (1991) 0.75
[Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study]. Med Klin (Munich) (1999) 0.75
[A specific tissue serotherapy. Dental pulp serum]. Bull Acad Dent (Paris) (1973) 0.75
[Changes in placental steroid metabolism caused by drugs (proceedings)]. Arch Gynakol (1977) 0.75
[Analysis of contemporary and future respiratory therapy]. Anasth Intensivther Notfallmed (1983) 0.75
Kefzol (cefazolin sodium, Lilly). Curr Ther Res Clin Exp (1975) 0.75
Determination of beta 2-receptor agonists in bovine urine and liver by gas chromatography-tandem mass spectrometry. J Chromatogr (1991) 0.75
Properties of two Clostridia strains acting as catalysts for the preparative stereospecific hydrogenation of 2-enoic acids and 2-alken-1-ols with hydrogen gas. Hoppe Seylers Z Physiol Chem (1978) 0.75
[Dental care of the handicapped in intubation anesthesia. The outpatient dental care of handicapped patients in intubation anesthesia at a rehabilitation center]. Schweiz Monatsschr Zahnmed (1990) 0.75
The reduction of allyl alcohols by Clostridium species is catalyzed by the combined action of alcohol dehydrogenase and enoate reductase. Hoppe Seylers Z Physiol Chem (1981) 0.75
[Aims and therapeutic limits in periodontal diseases]. Rev Fr Odontostomatol (1968) 0.75
[New connections of odonto-stomatology with various other scientific disciplines]. Rev Fr Odontostomatol (1967) 0.75
[Arterial macro-aneurysm complicated by premacular hemorrhage]. J Fr Ophtalmol (2013) 0.75
[Bacterial regrowth in drinking water. III. Reasons for regrowth with oligocarbotolerant bacteria]. Zentralbl Hyg Umweltmed (1989) 0.75
[54-year-old patient with anemia, jaundice, hepatosplenomegaly and paravertebral space-occupying lesions]. Internist (Berl) (1995) 0.75
[Fibrogenesis. Technic and applications]. Inf Dent (1966) 0.75